Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5279950 | 0.76 | TOP2A (0.35) | TOP2AALDH1A1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL5277066 | 0.74 | ALDH1A1 (0.32) | TOP2AALDH1A1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL5275800 | 0.74 | TOP2A (0.34) | TOP2AALDH1A1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL5278279 | 0.74 | — | — | |
| SCHEMBL5276140 | 0.74 | CYP1A2 (0.32) | TOP2AALDH1A1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL24221891 | 0.73 | ALDH1A1 (0.32) | TOP2AALDH1A1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL5281331 | 0.73 | TOP2A (0.37) | TOP2AALDH1A1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL5281315 | 0.73 | ALDH1A1 (0.32) | TOP2AALDH1A1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL24015389 | 0.73 | HPGD (0.32) | TOP2AALDH1A1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL5279667 | 0.73 | CYP1A2 (0.35) | TOP2AALDH1A1CYP1A2CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287341-A1 | GENETICALLY MODIFIED CELL LINES EXPRESSING AN EXOGENOUS SUBSTANCE AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230045277-A1 | COMPOUNDS, POLYMERS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
| EP-1859781-A2 | Brightening and/or colouring agent with triazoles | Henkel Kommanditgesellschaft auf Aktien (DE) | 2007-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230045277-A1 | COMPOUNDS, POLYMERS, DEVICES, AND USES THEREOF | PAH, BMP2, COL2A1 | TOP2A 2208/4885ALDH1A1 1058/4885CYP1A2 361/4885 |
| US-20230287341-A1 | GENETICALLY MODIFIED CELL LINES EXPRESSING AN EXOGENOUS SUBSTANCE AND USES THEREOF | ZFX, XPA, CTCF | TOP2A 2095/4885ALDH1A1 1825/4885CYP1A2 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.